Abstract:
Taking into account the urgency of the process of reforming the national health care system in the direction of implementing rational models of resource provision for patients, including the psychoneurological direction, as well as taking into account the objective processes of population aging, people's desire to improve the quality of their lives, the extension of the period their ability to work, the issue of analyzing the state of pharmaceutical support for dementia patients with Alzheimer's disease (AD) is socially important.